Gain Therapeutics, Inc. announced that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027. This funding includes the completion of the Phase 1b open-label extension in October 2026 and the initiation of a Phase 2 clinical study in the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and other diseases.

Gain Therapeutics, Inc. announced on June 29, 2026, that the U.S. Food and Drug Administration (FDA) authorized its Investigational New Drug application for GT-02287. This authorization allows the company to initiate Phase 2 clinical development of GT-02287 for Parkinson's disease in the United States, Australia, and Europe. The company anticipates the initiation of the Phase 2a study of oral GT-02287 in participants with early Parkinson's disease during the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on the development of therapeutic candidates for neurological and neurological-related diseases.